XOMA Royalty Corporation (NASDAQ:XOMA) Receives $61.60 Average Price Target from Brokerages

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned a consensus rating of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $61.60.

XOMA has been the subject of a number of research reports. UBS Group set a $76.00 price objective on XOMA Royalty in a research report on Tuesday, December 9th. TD Cowen upgraded XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Stifel Nicolaus set a $50.00 price target on shares of XOMA Royalty in a research report on Friday, December 12th. Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th.

XOMA Royalty Trading Up 3.7%

NASDAQ:XOMA opened at $29.77 on Friday. The company has a market cap of $354.56 million, a PE ratio of 20.39 and a beta of 0.86. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15. The company has a 50 day simple moving average of $26.15 and a two-hundred day simple moving average of $30.35. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.16. The firm had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $11.13 million. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%. Research analysts forecast that XOMA Royalty will post -1.41 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of XOMA. Woodline Partners LP grew its position in shares of XOMA Royalty by 7.9% during the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after acquiring an additional 12,284 shares during the period. Geode Capital Management LLC raised its holdings in XOMA Royalty by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock worth $5,132,000 after purchasing an additional 16,929 shares during the period. JPMorgan Chase & Co. lifted its position in XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 543 shares in the last quarter. Rhumbline Advisers grew its holdings in XOMA Royalty by 18.0% during the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after purchasing an additional 2,019 shares during the period. Finally, Panagora Asset Management Inc. bought a new stake in XOMA Royalty during the second quarter valued at about $463,000. Hedge funds and other institutional investors own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.